Cancer Research AACR Membership  Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhou, Y.
Right arrow Articles by Brattain, M. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhou, Y.
Right arrow Articles by Brattain, M. G.
[Cancer Research 65, 5848-5856, July 1, 2005]
© 2005 American Association for Cancer Research


Experimental Therapeutics, Molecular Targets, and Chemical Biology

Synergy of Epidermal Growth Factor Receptor Kinase Inhibitor AG1478 and ErbB2 Kinase Inhibitor AG879 in Human Colon Carcinoma Cells Is Associated with Induction of Apoptosis

Yunfei Zhou and Michael G. Brattain

Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York

Requests for reprints: Michael G. Brattain, Department of Molecular Pharmacology and Cancer Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263. Phone: 716-834-3044; Fax: 716-834-8857; E-mail: michael.brattain{at}roswellpark.org.

Previous studies have shown that constitutive activation of epidermal growth factor receptor (EGFR) and ErbB2 by elevated autocrine transforming growth factor-{alpha} (TGF-{alpha}) expression plays an important role in colon cancer progression. Coexpression of EGFR and ErbB2 is found in a subset of colon cancers and may cooperatively promote cancer cell growth and survival, as heterodimerization is known to provide for diversification of signal transduction. In this study, the EGFR-selective tyrosine kinase inhibitor (TKI) AG1478 inhibited cell growth of an aggressive human colon carcinoma cell line, FET6{alpha}S26X, which harbors constitutively activated EGFR after stable transfection with TGF-{alpha} cDNA. However, AG1478 failed to induce apoptosis in FET6{alpha}S26X cells at concentrations sufficient for cell growth inhibition and complete suppression of EGFR phosphorylation. Similarly, AG879, a selective ErbB2 TKI, was incapable of inducing apoptosis in FET6{alpha}S26X cells at concentrations sufficient to inhibit cell growth and ErbB2 phosphorylation. To test the hypothesis that targeting both ErbB family members would show better efficacy than targeting the single receptors, combinations of inhibitors at fixed ratios of 1:1, 5:1, and 10:1 of AG1478 and AG879, respectively, were compared with single drugs for inhibition of cell growth. All combinations resulted in synergistic effects as indicated by combination index analysis. Synergistic inhibition was associated with induction of apoptosis as reflected by poly(ADP-ribose) polymerase cleavage, caspase-3 activation, and Annexin V staining. Finally, Western blot analysis showed significant inhibition of phosphorylation of both EGFR and ErbB2 by the combination treatment. These data suggest that the strategy to target both EGFR and ErbB2 simultaneously might result in more efficient inhibition of tumor growth than to target single receptor alone.




This article has been cited by other articles:


Home page
Cancer Res.Home page
Y. P. Hu, S. B. Patil, M. Panasiewicz, W. Li, J. Hauser, L. E. Humphrey, and M. G. Brattain
Heterogeneity of Receptor Function in Colon Carcinoma Cells Determined by Cross-talk between Type I Insulin-like Growth Factor Receptor and Epidermal Growth Factor Receptor
Cancer Res., October 1, 2008; 68(19): 8004 - 8013.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
S. Goldoni, D. G. Seidler, J. Heath, M. Fassan, R. Baffa, M. L. Thakur, R. T. Owens, D. J. McQuillan, and R. V. Iozzo
An Antimetastatic Role for Decorin in Breast Cancer
Am. J. Pathol., September 1, 2008; 173(3): 844 - 855.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
I. N. Fleming, M. Hogben, S. Frame, S. J. McClue, and S. R. Green
Synergistic Inhibition of ErbB Signaling by Combined Treatment with Seliciclib and ErbB-Targeting Agents
Clin. Cancer Res., July 1, 2008; 14(13): 4326 - 4335.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
E. Needle, K. Piparo, D. Cole, C. Worrall, I. Whitehead, G. Mahon, and L. T. Goldsmith
Protein Kinase A-Independent cAMP Stimulation of Progesterone in a Luteal Cell Model Is Tyrosine Kinase Dependent but Phosphatidylinositol-3-Kinase and Mitogen-Activated Protein Kinase Independent
Biol Reprod, July 1, 2007; 77(1): 147 - 155.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
L. V. Sequist
Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
Oncologist, March 1, 2007; 12(3): 325 - 330.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Rajput, A. P. Koterba, J. I. Kreisberg, J. M. Foster, J. K.V. Willson, and M. G. Brattain
A Novel Mechanism of Resistance to Epidermal Growth Factor Receptor Antagonism In vivo
Cancer Res., January 15, 2007; 67(2): 665 - 673.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Zhou, S. Li, Y. P. Hu, J. Wang, J. Hauser, A. N. Conway, M. A. Vinci, L. Humphrey, E. Zborowska, J. K.V. Willson, et al.
Blockade of EGFR and ErbB2 by the Novel Dual EGFR and ErbB2 Tyrosine Kinase Inhibitor GW572016 Sensitizes Human Colon Carcinoma GEO Cells to Apoptosis
Cancer Res., January 1, 2006; 66(1): 404 - 411.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.